US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...

It’s important to speak with your healthcare professional about treatment plans. Anxiety disorders are among the most common mental health conditions in the United States. It’s estimated that ...

In past trials, ketamine intravenous treatment has shown promise, with 64% of depression patients in trials experiencing ...

A new study supports previous research that exposure and response prevention (ERP) for obsessive-compulsive disorder is ...

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...

How long an anxiety attack lasts depends on the person and their coping mechanisms. Find actionable suggestions to overcome ...

Research reveals new connections between the gut and brain, suggesting more targeted depression and anxiety treatments, and a ...

Exposure therapy can help patients conquer their fears, but it isn’t effective for everyone. Researchers are exploring how ...

Caroline Crampton developed excessive health anxiety after being treated for cancer as a teen. In A Body Made of Glass she ...

In animal studies, boosting serotonin in the cells that line the gut reduced anxious and depressive-like behaviors without causing cognitive or gastrointestinal side effects.

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...